Molecular Partners Ag (MOLN) Non-Current Assets (2020 - 2026)
Molecular Partners Ag's (MOLN) quarterly Non-Current Assets came in at $5.4 million in Q2 2026, up 21.23% year-over-year from $4.5 million in Q2 2025, and down 10.64% quarter-over-quarter from $6.0 million in Q1 2026.
Analysis
Molecular Partners Ag (MOLN) Non-Current Assets (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Non-Current Assets for 7 consecutive years, with $5.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non-Current Assets rose 21.23% year-over-year to $5.4 million in Q2 2026; TTM through Jun 2026 was $5.4 million, a 21.23% increase from a year earlier, with the FY2025 full-year figure at $6.3 million, up 30.69% from the prior year.
- Non-Current Assets was $5.4 million for Q2 2026 at Molecular Partners Ag, down from $6.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $8.9 million in Q1 2022 and troughed at $4.0 million in Q3 2025.
- A 5-year average of $6.3 million and a median of $6.4 million in 2025 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets slipped 27.03% in 2024 and soared 35.0% in 2025, its largest moves.
- Over 5 years, Non-Current Assets stood at $7.8 million in 2022, then fell by 14.73% to $6.6 million in 2023, then decreased by 27.03% to $4.8 million in 2024, then soared by 35.0% to $6.5 million in 2025, then declined by 17.53% to $5.4 million in 2026.
- The last three Non-Current Assets figures came in at $5.4 million (Q2 2026), $6.0 million (Q1 2026), and $6.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Molecular Partners Ag | 156.54 Mn | 156.54 Mn | - | 5.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.40 Mn |
| Mar 31, 2026 | 6.04 Mn |
| Dec 31, 2025 | 6.54 Mn |
| Sep 30, 2025 | 3.99 Mn |
| Jun 30, 2025 | 4.45 Mn |
| Mar 31, 2025 | 4.61 Mn |
| Dec 31, 2024 | 4.85 Mn |
| Sep 30, 2024 | 5.40 Mn |
| Jun 30, 2024 | 5.54 Mn |
| Mar 31, 2024 | 6.21 Mn |
| Dec 31, 2023 | 6.64 Mn |
| Sep 30, 2023 | 7.00 Mn |
| Jun 30, 2023 | 7.38 Mn |
| Mar 31, 2023 | 7.63 Mn |
| Dec 31, 2022 | 7.79 Mn |
| Sep 30, 2022 | 7.74 Mn |
| Jun 30, 2022 | 8.11 Mn |
| Mar 31, 2022 | 8.92 Mn |
| Dec 31, 2021 | 9.19 Mn |
| Sep 30, 2021 | 9.49 Mn |